Polyrizon

Company Overview

Snapshot

Founded in March 2020 by Tomer Izraeli, Polyrizon is a biotech company with 1–10 employees. The company has raised $27.03M across nine funding rounds and went public on NASDAQ in October 2024.

Business overview

Polyrizon is a biotech company specializing in the development and commercialization of innovative intranasal products within the Health Tech & Life Sciences sector. Its core technologies include the Capture & Contain (C&C) platform, a natural 3D polymeric network designed to create a physical barrier against airborne contaminants like allergens and viruses, and the Trap & Target (T&T) platform, a drug delivery system for highly effective targeted delivery of medicines with long residence times on mucosal tissue. The company's products are designed to protect the human body and improve therapeutic effects, serving markets in pharmaceuticals and medical products.

Strategic signal

Polyrizon is actively advancing its clinical development pipeline, evidenced by the recent securing of its first U.S. clinical site for the NASARIX™ Allergy Blocker clinical trial in May 2026. This move signals a significant step towards commercialization and regulatory approval for its innovative intranasal products, demonstrating a clear forward trajectory in bringing its technology to market.

Company Intelligence Q&A

What was a significant recent development for Polyrizon's clinical trials?

In June 2026, Polyrizon secured three U.S. sites for its NASARIX™ trial, demonstrating strong clinical progress for its allergy blocker.

Has Polyrizon recently expanded its intellectual property?

Yes, in June 2026, Polyrizon received notice of U.S. patent publication for its mucoadhesive drug delivery platform, and in May 2026, announced a U.S. patent expansion for its intranasal drug delivery platform.

What is Polyrizon's current status regarding regulatory approvals for its allergy blocker?

In June 2026, Polyrizon received Central IRB Approval for its Allergy Blocker Clinical Trial, marking significant progress in its regulatory pathway.

What strategic partnership did Polyrizon announce in March 2026?

In March 2026, Polyrizon signed an agreement with a leading global preclinical CRO as part of its clinical development program, indicating a focus on accelerating its product pipeline.

What was a key financial event for Polyrizon in October 2024?

In October 2024, Polyrizon announced the closing of a $4.2 million Initial Public Offering and began trading on the Nasdaq Capital Market under the ticker “PLRZ”.